Home › Non-Small Cell Lung Cancer › NCT05265429

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

RecruitingObservational study

Who can join

Ages 15 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Age 45 and under at lung cancer diagnosis
* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
* Provision of written informed consent
* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion Criteria:

* Individuals who decline to sign consent
* Individuals who are unable to give consent or assent and are without a designated healthcare proxy
* Compromise of patient diagnosis or staging if tissue is used for research

About the study

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

What is being tested

Data and Specimen Collection (genetic)

Sponsor: Dana-Farber Cancer Institute · Participants: 500 · Started: Jan 1, 2023

Contact the study team

Pasi A Janne, MD, PhD · Phone: 617-632-6036

Official record on ClinicalTrials.gov — NCT05265429

Locations in the U.S.

Massachusetts

Beth Israel Deaconess Medical Center, Boston (Not yet recruiting)
Brigham and Women's Hospital, Boston (Not yet recruiting)
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.